Compass Therapeutics Files Q1 2025 10-Q
Ticker: CMPX · Form: 10-Q · Filed: May 8, 2025 · CIK: 1738021
| Field | Detail |
|---|---|
| Company | Compass Therapeutics, Inc. (CMPX) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Compass Therapeutics filed its Q1 2025 10-Q. Check financials and pipeline updates.
AI Summary
Compass Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its clinical programs. Specific financial figures and operational details are available within the full filing.
Why It Matters
This filing provides investors with the latest financial health and operational progress of Compass Therapeutics, crucial for understanding its current standing and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Compass Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Players & Entities
- Compass Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- 001-39696 (company) — SEC File Number
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is for the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed with the SEC on May 8, 2025.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0001738021.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2836, for Biological Products (No Diagnostic Substances).
What is the company's business address?
The company's business address is 80 Guest Street, Boston, MA 02135.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Compass Therapeutics, Inc. (CMPX).